LML. Meziane

L. Meziane

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


L. Meziane has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • A. Caudron

    Basel

    1 shared publication
  • Ali Dadban

    Department of Dermatology, Amiens University Hospital, Amiens, France

    1 shared publication
  • C. Lok

    Department of Dermatology Amiens University Medical Centre South Hospital and University Picardie Jules Verne Amiens France

    1 shared publication
  • F. Dhaille

    Department of Dermatology Amiens University Medical Centre South Hospital and University Picardie Jules Verne Amiens France

    1 shared publication
  • G. Chaby

    Department of Dermatology Amiens University Medical Centre South Hospital and University Picardie Jules Verne Amiens France

    1 shared publication
  • M. Jourdan

    Department of Dermatology Amiens University Medical Centre South Hospital and University Picardie Jules Verne Amiens France

    1 shared publication

Latest Publications

  • Open Access

    Febrile Ulceronecrotic Mucha-Habermann Disease: Treatment with Infliximab and Intravenous Immunoglobulins and Review of the Literature

    by L. Meziane, A. Caudron, F. Dhaille, M. Jourdan, A. Dadban, C. Lok, G. Chaby

    Febrile ulceronecrotic Mucha-Habermann disease (FUMHD) is a rare subtype of pityriasis lichenoides et varioliformis acuta, characterized by an acute onset of ulceronecrotic papules, rapidly coalescing into large ulcers with necrotic crusts, associated with high fever and severe systemic symptoms. We report a case of a 65-year-old woman with a resistant form of FUMHD successfully treated with a tumor necrosis factor-α (TNFα) inhibitor (infliximab). After 1 year of treatment, because of the recurrence of lesions and -occurrence of severe sepsis, we decided to change the therapeutic procedure by introducing intravenous immunoglobulin witch induced a spectacular improvement. Only few cases of FUMHD treated with intravenous immunoglobulin have been reported to date. In our case, we describe the first utilization of TNFα inhibitors in the treatment of FUMHD: TNFα inhibitors may be useful, particularly in resistant cases. Further reports are required to confirm this potential therapeutic option.